<DOC>
	<DOCNO>NCT00581165</DOCNO>
	<brief_summary>Evaluate ( ) safety etanercept patient moderate severe psoriasis Spain ; ( ii ) incidence adverse event report patient , ( iii ) role age concomitant therapy might play development adverse reaction .</brief_summary>
	<brief_title>Study Evaluating Safety Etanercept Treatment Patients With Moderate Severe Psoriasiswith Etanercept</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>1 . Informed consent sign patient prior study entry 2 . 18 year age old screen visit 3 . Patients moderate severe psoriasis 4 . Patients fail conventional systemic treatment 5 . Patients contraindication conventional systemic therapy 6 . Patients intolerant conventional systemic therapy 7 . A negative serum pregnancy test screen woman childbearing potential 8 . Able selfinject study drug designee 9 . In opinion investigator , patient able comply requirement protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>